ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01440712
Recruitment Status : Completed
First Posted : September 26, 2011
Last Update Posted : July 15, 2014
Sponsor:
Information provided by (Responsible Party):
Sebastiano Biondo, Hospital Universitari de Bellvitge

Brief Summary:
The purpose of this trial is to determine whether the water-soluble contrast (gastrografin) is more effective in the treatment of postoperative ileus than the conventional one.

Condition or disease Intervention/treatment Phase
Postoperative Ileus Drug: Gastrografin Drug: physiological serum Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized Double Blind Study of the Effect of Gastrografin on Postoperative Ileus After Colorectal Surgery
Study Start Date : December 2011
Actual Primary Completion Date : November 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Gastrografin
Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
Drug: Gastrografin
Administration of 100 ml of gastrografin by the nasogastric tube, only once.

Placebo Comparator: physiological serum
Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
Drug: physiological serum
Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.




Primary Outcome Measures :
  1. Time to resolution of postoperative ileus after surgery defined as time to tolerance of oral intake of solid or semisolid food [ Time Frame: While the patient is admitted to the hospital. An average of 11 days since the intervention. ]

Secondary Outcome Measures :
  1. Hospital stay after diagnosis of ileus [ Time Frame: While the patient is admitted to the hospital. An average of 11 days since the intervention. ]
    Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged.

  2. Percentage of patients requiring total parenteral nutrition. [ Time Frame: While the patient is admitted to the hospital. An average of 11 days since the intervention ]
    Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged

  3. Presence of postoperative pain and analgesic required [ Time Frame: While the patient is admitted to the hospital. An average of 11 days since the intervention ]
    Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged

  4. Percentage of mortality during hospitalization. [ Time Frame: While the patient is admitted to the hospital. An average of 11 days since the intervention ]
    Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients with postoperative ileus after colorectal surgery, defined as the presence from the third postoperative day, abdominal distension, nausea, vomiting with or without abdominal pain or discomfort by dilation of bowel loops, confirmed radiology of the abdomen, and which are: Age > 18 years Patients undergoing laparotomy or laparoscopy for the following variants of colorectal disease with or without stoma:

    1. Neoplasia.
    2. Inflammatory disease.
    3. Diverticular disease. Patients who have been treated with standard PCA as postoperative analgesia. Signed informed consent. Undergoing elective or scheduled

Exclusion Criteria:

  • Patient's refusal to sign informed consent
  • Pregnancy or lactation
  • Hypersensitivity to iodinated contrast agents (it´s the only contraindication to oral Gastrografin) Presence of other problems that justify the etiology of postoperative ileus:

    1. Anastomotic leakages.
    2. Mesenteric vascular disease.
    3. Incarcerated hernias.
    4. Intra-abdominal abscesses or collections.
    5. Metabolic or electrolyte disturbances. If during the course of the study one of the reasons previously cited as the etiology of postoperative ileus is present, the patient shall also be excluded. Also excluded patients undergoing emergency surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01440712


Locations
Spain
Hospital Universitari Bellvitge
L´Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Universitari de la Vall d´Hebron
Barcelona, Spain, 08035
Hospital Universitari de Girona
Girona, Spain, 17007
Sponsors and Collaborators
Hospital Universitari de Bellvitge
Investigators
Principal Investigator: Sebastiano Biondo, Dr. Bellvitge University Hospital

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sebastiano Biondo, Principal investigator, Hospital Universitari de Bellvitge
ClinicalTrials.gov Identifier: NCT01440712     History of Changes
Other Study ID Numbers: Ileus_gastro
2010-024096-87 ( EudraCT Number )
First Posted: September 26, 2011    Key Record Dates
Last Update Posted: July 15, 2014
Last Verified: July 2014

Keywords provided by Sebastiano Biondo, Hospital Universitari de Bellvitge:
Gastrografin
Postoperative ileus
Colo-rectal surgery
Effects on morbidity and mortality of postoperative ileus

Additional relevant MeSH terms:
Ileus
Intestinal Obstruction
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases